Published in Clin Exp Immunol on March 01, 1971
A defect of B-lymphocyte transport of aggregated HGG into germinal centres in NZB and NZB x NZW F 1 hybrid mice. Clin Exp Immunol (1972) 1.38
Age-decrease of cells sensitive to an autoantibody-specific for thymocytes and thymus-dependent lymphocytes in NZB mice. Clin Exp Immunol (1972) 1.14
Effect of age on cell-mediated immunity in long-lived mice. Clin Exp Immunol (1975) 1.09
Monoclonal macroglobulinemia in NZB-NZW F1 mice. J Exp Med (1973) 1.02
Characterization of Gazdar murine sarcoma virus by nucleic acid hybridization and analysis of viral expression in cells. J Virol (1977) 0.93
Independent appearance of anti-thymocyte and anti-RNA antibodies in NZB/NZW F1 mice. Immunology (1975) 0.88
Alteration in DNA synthetic response of thymocytes from NZB mice of different ages. Proc Natl Acad Sci U S A (1973) 0.85
Hyperactive T-cell function in young NZB mice; increased proliferative responses to allogenic cells. Clin Exp Immunol (1976) 0.83
Monoclonal IgM surface immunoglobulin on lymphocytes of aging NZB mice and its induction in young mice by RNA. Clin Exp Immunol (1974) 0.83
In vitro studies on the phagocytosis of Staphylococcus aureus by peritoneal macrophages of New Zealand mice. Immunology (1973) 0.79
Autoimmunity and tumor resistance. 3-Methylcholanthrene tumorigenesis in New Zealand Black mice. Am J Pathol (1978) 0.77
The immunology and pathology of NZB mice. Adv Immunol (1968) 9.04
Pathogenesis of the glomerulonephritis of NZB/W mice. J Exp Med (1968) 8.91
Studies on cellular immunity and its serum mediated inhibition in Moloney-virus-induced mouse sarcomas. Int J Cancer (1969) 2.80
Relative inability to induce tolerance in adult NZB and NZB-NZW F1 mice. J Exp Med (1969) 2.78
The appearance of immunological competence at an early age in New Zealand black mice. Clin Exp Immunol (1968) 2.73
Deficient immunologic functions of NZB mice. Proc Soc Exp Biol Med (1968) 2.41
Synergy among lymphoid cells mediating the graft-versus-host response. I. Synergy in graft-versus-host reactions produced by cells from NZB-Bl mice. J Exp Med (1970) 2.15
DNA-binding assay for detection of anti-DNA antibodies in NZB-NZW F1 mice. J Immunol (1969) 2.13
Response of NZB mice to foreign antigen and development of autoimmune disease. J Reticuloendothel Soc (1969) 1.75
Autoimmune phenomena and renal disease in mice. Role of thymectomy, aging, and involution of immunologic capacity. Lab Invest (1970) 1.69
Induction and regression of primary moloney sarcoma virus-induced tumors in mice. Cancer Res (1967) 1.60
Immunologic, virologic, and pathologic studies of regression of autochthonous Moloney sarcoma virus-induced tumors in mice. Cancer Res (1968) 1.57
The immune response in NZB and NZB x C3H F1-hybrid mice as measured by the haemolysin plaque technique. Int Arch Allergy Appl Immunol (1966) 1.55
Response of NZB and NZB-NZW spleen cells to mitogenic agents. J Immunol (1970) 1.54
Immune response to a soluble protein antigen in NZB mice. Nature (1968) 1.51
GROWTH AND SENESCENCE OF THE PRIMARY ANTIBODT-FORMING POTENTIAL OF THE SPLEEN. J Immunol (1964) 1.50
Depletion of long-lived lymphocytes in old New Zealand black mice. Clin Exp Immunol (1970) 1.44
Study of autoimmune disease in New Zealand mice. I. Genetic features and natural history of NZB, NZY and NZW strains and NZB-NZW hybrids. J Invest Dermatol (1968) 1.34
The immune response in NZBxNZW F1 hybrid mice. Clin Exp Immunol (1969) 1.30
A deficient development of the thymic epithelium and auto-immune disease in NZB mice. J Pathol Bacteriol (1966) 1.23
Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice. Cancer Res (1969) 1.17
Rapid loss of tolerance induced in weanling NZB and B-W F1 mice. Science (1969) 1.16
Anti-nuclear antibodies in mice. I. Influence of age and possible genetic factors on spontaneous and induced responses. J Immunol (1968) 1.13
Some biologic, immunogenic, and morphologic effects in mice after infection with a murine sarcoma virus. I. Biologic and immunogenic studies. J Natl Cancer Inst (1968) 1.10
Quantitative dose-response relationships of murine sarcoma virus (Moloney) in BALB/c mice. J Natl Cancer Inst (1969) 1.07
Increased 7S antibody response to sheep erythrocytes in the 2-month-old NZB mouse. Clin Exp Immunol (1969) 0.98
Reduced immune potential of aged mice: significance of morphologic changes in lymphatic tissue. Proc Soc Exp Biol Med (1967) 0.90
Impaired recovery of plaque-forming cells in New Zealand mice given cyclophosphamide. J Immunol (1970) 0.81
The response of NXW-NZB F1 hybrid mice to a murine sarcoma virus. Int Arch Allergy Appl Immunol (1970) 0.81
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1980) 30.08
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis (2002) 20.48
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res (1987) 10.80
p53: a frequent target for genetic abnormalities in lung cancer. Science (1989) 7.51
Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature (1984) 6.23
Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood (1980) 6.17
Measurement of serum DNA-binding activity in systemic lupus erythematosus. N Engl J Med (1969) 6.16
Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res (1985) 5.02
L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature (1985) 4.66
Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp Med (1978) 4.28
Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science (1988) 4.26
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst (2001) 4.14
Differentiation and characterization of autoantibodies and their antigens in Sjögren's syndrome. Arthritis Rheum (1976) 4.02
The pathogenesis of autoimmunity in New Zealand black mice. Curr Top Microbiol Immunol (1974) 3.98
Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell (1998) 3.86
The histopathology of Sjögren's syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol (1974) 3.82
Assignment of direct and facilitated hemolytic plaques in mice to specific immunoglobulin classes. J Immunol (1968) 3.81
Continuous, clonal, insulin- and somatostatin-secreting cell lines established from a transplantable rat islet cell tumor. Proc Natl Acad Sci U S A (1980) 3.39
Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am J Pathol (1985) 3.31
NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl (1996) 3.24
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A (1990) 3.03
Molecular genetics of small cell lung carcinoma. Semin Oncol (2001) 3.02
Extrasalivary lymphoid abnormalities in Sjögren's syndrome (reticulum cell sarcoma, "pseudolymphoma," macroglobulinemia). Am J Med (1967) 2.92
Xerostomia in Sjögren's syndrome. Evaluation by sequential salivary scintigraphy. JAMA (1971) 2.89
Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst (1997) 2.83
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene (2008) 2.83
Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res (2001) 2.80
Relative inability to induce tolerance in adult NZB and NZB-NZW F1 mice. J Exp Med (1969) 2.78
Impaired Lymphocyte Transformation and Delayed Hypersensitivity in Sjögren's Syndrome. J Clin Invest (1967) 2.77
Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum (1988) 2.77
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res (1998) 2.72
Immunologic and viral factors in the pathogenesis of systemic lupus erythematosus. Arthritis Rheum (1971) 2.66
Disordered immunologic regulation and autoimmunity. Transplant Rev (1976) 2.62
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res (1987) 2.56
Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res (2001) 2.50
Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene. J Exp Med (1981) 2.46
Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst (2000) 2.45
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol (2007) 2.43
Fractionation of splenic antibody-forming cells on glass bead columns. J Immunol (1967) 2.41
Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest (1998) 2.39
B cells expressing CD5 are increased in Sjögren's syndrome. Arthritis Rheum (1988) 2.37
Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J Clin Invest (1977) 2.33
The pathogenesis of autoimmunity in New Zealand mice, I. Induction of antinucleic acid antibodies by polyinosinic-polycytidylic acid. Proc Natl Acad Sci U S A (1969) 2.31
Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest (1997) 2.30
Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res (2000) 2.24
Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst (1995) 2.18
Synergy among lymphoid cells mediating the graft-versus-host response. I. Synergy in graft-versus-host reactions produced by cells from NZB-Bl mice. J Exp Med (1970) 2.15
DNA-binding assay for detection of anti-DNA antibodies in NZB-NZW F1 mice. J Immunol (1969) 2.13
Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res (1986) 2.12
Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res (1985) 2.12
Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res (1980) 2.10
Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene (1998) 2.10
Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res (1992) 2.09
High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science (1981) 2.07
Detection and sequencing of p53 gene mutations in bronchial biopsy samples in patients with lung cancer. Chest (1993) 2.06
Identification of mouse chromosomes required for murine leukemia virus replication. Cell (1977) 2.05
Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst (1999) 2.03
beta-Estradiol reduces natural killer cells in mice. J Immunol (1978) 2.02
Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet (1982) 2.02
Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science (1982) 2.02
The spectrum of benign to malignant lymphoproliferation in Sjögren's syndrome. Clin Exp Immunol (1972) 2.01
Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci U S A (1986) 1.96
Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst (2000) 1.94
Filter radioimmunoassay for antibodies to reovirus RNA in systemic lupus erythematosus. Arthritis Rheum (1974) 1.92
Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunol (1981) 1.89
Establishment and characterization of a murine hybridoma secreting monoclonal anti-DNA autoantibody. J Immunol (1980) 1.88
Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res (2001) 1.84
Peripheral airway cell marker expression in non-small cell lung carcinoma. Association with distinct clinicopathologic features. Am J Clin Pathol (1992) 1.84
Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene (1999) 1.83
Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J Natl Cancer Inst (1995) 1.83
Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung. Proc Natl Acad Sci U S A (1981) 1.83
Combined modality therapy with electron-beam irradiation and systemic chemotherapy for cutaneous T-cell lymphomas. Cancer Treat Rep (1979) 1.82
Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol (1984) 1.81
Immunological regulation of spontaneous antibodies to DNA and RNA. II. Sequential switch from IgM to IgG in NZB/NZW F1 mice. Immunology (1977) 1.80
The neuropathy of Sjögren's syndrome. Trigeminal nerve involvement. Ann Intern Med (1969) 1.79
Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene (1991) 1.79
High interferon producing line of transformed murine cells. J Gen Virol (1972) 1.79
The clearance and localization of nucleic acids by New Zealand and normal mice. Clin Exp Immunol (1972) 1.74
Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst (1993) 1.73
Telomerase activity in human breast tumors. J Natl Cancer Inst (1996) 1.73
Renal tubular acidosis, glomerulonephritis and immunologic factors in Sjögren's syndrome. Arthritis Rheum (1968) 1.72
The oral component of Sjögren's syndrome. Oral Surg Oral Med Oral Pathol (1975) 1.70
Cyclophosphamide in lupus nephritis: a controlled trial. Ann Intern Med (1971) 1.70
Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA (1995) 1.69
The pathogenesis of autoimmunity in New Zealand mice. 3. Factors influencing the formation of anti-nucleic acid antibodies. Immunology (1971) 1.68
Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res (1995) 1.67
High-frequency transfection and cytopathology of the hepatitis B virus core antigen gene in human cells. Science (1983) 1.67
Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proc Natl Acad Sci U S A (2001) 1.67
Intermediate filament and cross-linked envelope expression in human lung tumor cell lines. Cancer Res (1985) 1.66
FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res (1997) 1.66
Advances in the diagnosis and concept of Sjögren's syndrome (autoimmune exocrinopathy). Bull Rheum Dis (1980) 1.64
Sex-related differences in bronchial epithelial changes associated with tobacco smoking. J Natl Cancer Inst (1999) 1.64
T and B lymphocytes in peripheral blood and tissue lesions in Sjögren's syndrome. J Clin Invest (1974) 1.63
Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene (1992) 1.63
DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene (2008) 1.63
Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci U S A (1990) 1.63
Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res (1995) 1.62
Interleukin-2 in rheumatoid arthritis: production of and response to interleukin-2 in rheumatoid synovial fluid, synovial tissue and peripheral blood. Clin Exp Immunol (1985) 1.61